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Introduction
Approximately 8.3 million adult drug users were employed in the
United States in 1997.1 These employees cost U.S. employers $100
billion annually due to higher costs related to turnover, absenteeism,
accidents, decreased productivity, and health care. 2 Consequently, in
recent years, testing of job applicants and employees for the presence of
illegal substances has increased. Pre-employment drug screening is
conducted by 95% of Fortune 500 companies, and more than six
million workers are subject to mandatory testing because of
governmental requirements. 3 Moreover, 81% of the corporations
responding to an American Management Association survey used some
form of drug testing.4
To be acceptable for detecting the use of unlawful substances, drug
tests must accurately discriminate between those who use drugs and
those who do not.5 False positive errors in the testing process are
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1 See U.S. Dep't of Health and Human Services, National Household Survey on Drug
Abuse (1998).
2 See Jane Easter Bahls, Drugs in the Workplace, 43(2) H.R. Mag. 80 (1998); Steve Bates,
House Passes Bill to Curb Workplace Substance Abuse, 86(8) Nation's Bus. 8 (1998); David
Warner, The War on Drugs Wants You, 84(2) Nation's Bus. 54 (1996); Workplace Substance
Abuse: A Snapshot, 17(6) Behav. Health Mgmt. 14 (1997).
3 See Bahls, supra note 2; Kevin B. Zeese, Drug Testing Legal Manual (1995).
4 See American Mgmt. Ass'n, 1996 AMA Survey on Workplace Drug Testing and Drug
Abuse Policies (1996).
5 See Darold T. Barnum & John M. Gleason, Analyzing Proficiency Criteria of Health
Technology Systems: The Case of Drug Testing, 46 IEEE Trans. Engin. Mgmt. 359 (1999);
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especially serious, given the systems of jurisprudence in the United
States and other industrialized nations which require individuals be
presumed innocent until proven guilty.6 Consequently, empirical
studies are routinely conducted to estimate the proficiency of drug-
testing laboratories. Many studies of drug-testing laboratories in the
United States, and more recently in various European countries, have
been published in major biomedical journals in the last two decades.7
Moreover, laboratory proficiency studies are routinely conducted by
government agencies as part of laboratory certification processes.
Darold T. Barnum & John M. Gleason, The Credibility of Drug Tests: A Multi-stage
Bayesian Analysis, 47 Indus. Lab. Rel. Rev. 610 (1994); John M. Gleason & Darold T.
Barnum, A Probabilistic Analysis of Multiple-Drug Testing Procedures in Sports Doping
Control, 1 Int'l Trans. Operat. Research, 395 (1994); John M. Gleason & Darold T. Barnum,
Estimating Actual Rates of Drug Use, 27 Socio-Economic Plan. Sci. 199 (1993); John M.
Gleason & Darold T. Barnum, Predictive Probabilities in Employee Drug Testing, 2 RISK 3
(1991); Lennart E. Henriksson, Drug Testing and Grievance Rates, 23 J. Collect. Negot. Pub.
Sector 211 (1994).
6 See Robert P. De Cresce et al., Drug Testing in the Workplace (1989); Tia S. Denenberg
& Richard V. Denenberg, Alcohol and Other Drugs: Issues in Arbitration (1991); Helen Elkiss
& Joseph Yaney, Recent Trends in Arbitration of Substance Abuse Grievances, 42 Lab. L.J.
556 (1991); Frank Elkouri & Edna Asper Elkouri, HowArbitration Works (1985); Marvin F.
Hill & Anthony V. Sinicropi, Evidence in Arbitration (1987); Bureau of National Affairs, The
Developing Labor Law (Charles J. Morris ed., 1983); Kenneth W. Thornicroft, Arbitrators
and Substance Abuse Discharge Grievances: An Empirical Assessment, 14(4) Lab. Stud. J. 40
(1989). See Zeese, supra note 3.
7 See, e.g., Roser Badia et al., Survey on Drugs-of-Abuse Testing in the European Union,
27 J. Analyt. Tox. 117 (1998); Joe D. Boone et al., Laboratory Evaluation and Assistance
Efforts: Mailed, On-site and Blind Proficiency Testing Surveys Conducted by the Centers for
Disease Control, 72 Am. J. Pub. Health 1364 (1982); D. Burnett et al., A Survey of Drugs of
Abuse Testing by Clinical Laboratories in the United Kingdom, 27 Annals Clin. Biochem. 213
(1990); Kenneth H. Davis, Richard L. Hawks & Robert V. Blanke, Assessment of Laboratory
Quality in Urine Drug Testing, 260 JAMA 1749 (1988); Christopher S. Frings, Robert M.
White & Danielle J. Battaglia, Status of Drugs-of-Abuse Testing in Urine: An AACC Study,
33 Clin. Chem. 1683 (1987); Christopher S. Frings, Danielle J. Battaglia & Robert M. White,
Status of Drugs-of-Abuse Testing in Urine Under Blind Conditions: An AACC Study, 35
Clin. Chem. 891 (1989); Edward Gottheil, Glenn R. Caddy & Deborah L. Austin, Fallibility
of Urine Drug Screens in Monitoring Methadone Programs, 236 JAMA 1035 (1976); Hugh J.
Hansen, Samuel P. Caudill & Joe D. Boone, Crisis in Drug Testing: Results of CDC Blind
Study, 253 JAMA 2382 (1985); Susan J. Knight et al., Industrial Employee Drug Screening:
A Blind Study of Laboratory Performance Using Commercially Prepared Controls, 32 J.
Occup. Med. 715 (1990); P. Lafolie & 0. Beck, Deficient Performance of Drugs of Abuse
Testing in Sweden: An External Control Study, 54 Scandinavian J. Clin. Lab. Invest. 251
(1994); Louis C. LaMotte et al., Comparison of Laboratory Performance with Blind and Mail-
distributed Proficiency Testing Samples, 92 Pub. Health Rep. 554 (1977); J. Segura et al.,
Proficiency Testing on Drugs of Abuse: One Year's Experience in Spain, 35 Clin. Chem. 879
(1989); J. F. Wilson et al., External Quality Assessment of Techniques for the Detection of
Drugs of Abuse in Urine, 31 Annals Clin. Biochem. 335 (1994); J.F. Wilson et al.,
Performance of Techniques Used to Detect Drugs of Abuse in Urine: Study Based on
External Quality Assessment, 37 Clin. Chem. 442 (1991).
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The focus of the proficiency studies is to determine the risk of false
positive and false negative errors in the laboratories' testing processes.
This article reports the results of a Performance Indicator Analysis 8 of
proficiency criteria in the drug-testing-laboratory certification process
mandated by the U.S. Department of Health and Human Services
(DHHS). We examine the problems inherent in the use of laboratories
as the unit of analysis, and identify conditions under which these
problems may result in misleading conclusions, incorrect decisions, and
inappropriate demands for corrective actions.
The DHHS Guidelines
The importance of accurate drug testing in clinical laboratories in
the United States is reflected in federal policy through the Clinical
Laboratory Improvement Amendments of 1988 (and the
implementation of the regulations in 1993), in policies and procedures
required by the U.S. Department of Transportation that mandate
testing of safety sensitive employees in the transportation industry, and
in the mandatory guidelines promulgated by the DHHS for federal
workplace drug-testing programs. 9
The DHHS guidelines specify scientific and technical requirements
for federal agencies' workplace drug-testing programs. These guidelines
also establish a certification process that applies to laboratories that
perform drug testing for federal agencies. The guidelines require that
random drug-testing programs test for marijuana and cocaine. The
programs also may test for opiates, amphetamines, and phencyclidine,
and for other drugs when tests are conducted on the basis of reasonable
suspicion, accident, or safe practice. 10
The importance of accuracy of the testing process is recognized in
the DHHS guidelines: "Reliable discrimination between the presence,
or absence, of specific drugs ... is critical, not only to achieve the goals
of the testing program but to protect the rights of the Federal
8 See Darold T. Barnum & John M. Gleason, Analyzing Proficiency Criteria of Health
Technology Systems: The Case of Drug Testing, 46 IEEE Trans. Engin. Mgnrt. 359 (1999).
9 See P. Bachner, Is It Time to Turn the Page on CLIA 1988?, 279 JAMA 473 (1998);
Procedures for Transportation Workplace Drug Testing Programs, Quality Assurance, and
Quality Control, 49 C.F.R. § 40.31 (1997); Mandatory Guidelines for Federal Workplace
Drug Testing Programs, 59 Fed. Reg. 29908, 29918, Subpart B, 2.1(a) (une 9, 1994).
10 See 59 Fed. Reg. 29908, Subpart B, 2.1(a).
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employees being tested." 11 Furthermore, the guidelines indicate that
drug testing should be considered a special application of forensic
toxicology, because "of the impact of a positive test result on an
individual's livelihood or rights, together with the possibility of a legal
challenge of the results." 12 Accordingly, the DHHS laboratory
certification program provides stringent proficiency standards that
must be satisfied by laboratories involved in drug testing for federal
agencies.
However, criteria used in proficiency-testing processes are often
flawed. For example, we developed a process we refer to as
Performance Indicator Analysis (PIA) to analyze drug-testing accuracy
measures that were used in laboratory proficiency studies published in
peer-reviewed medical and scientific journals from 1976 through 1998.
We found that most indicators of proficiency are faulty, and that
flawed indicators are present in every study. 13
In this paper, we use PIA to identify problems with the DHHS
proficiency-testing criteria. The PIA identifies a variety of proficiency-
criteria problems that result when laboratories are considered as the
units of analysis. Specifically, there are conditions under which
laboratories with equal degrees of accuracy will have different false-
positive reporting probabilities. Moreover, false-negative reporting
probabilities may differ between laboratories, resulting in cases in which
a superior-performing laboratory yields results which suggest lower
proficiency than an inferior laboratory.
False Positives and the DHHS Guidelines
The effect of a false positive depends on the certification status of
the laboratory. During the initial DHHS certification process, any false
positive that occurs during proficiency testing disqualifies a laboratory
from further consideration. On the other hand, the DHHS
proficiency-testing requirements specify that if any false positives result
from blind challenges sent to a certified laboratory, then that
laboratory will be identified as out of compliance and corrective actions
must be taken. 14
I1 Id. at 29925, Subpart C, 3.2(b).
12 Id., Subpart C, 3.2(c).
13 See Barnum & Gleason, supra note 8.
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The guidelines require that laboratories processing more specimens
receive more blind challenges. 15 Consequently, the PIA indicates that
the probability that a laboratory reports a false positive is higher for the
higher-volume laboratories, even though these laboratories identify a
negative challenge at the same rate as lower-volume laboratories.
For example, assume that 20 blank proficiency test specimens (a
blank specimen is one that does not contain drugs) are being tested for
five drugs each, and that each drug test conducted by the laboratory
has an individual specificity of 0.9999 (where specificity is the
probability of a negative test result, given that the drug is not in the
specimen); that is, there is only one chance in 10,000 that a negative
drug challenge will yield a positive test result. It follows then that the
probability of an individual specimen being correctly declared negative
(that is, the probability of no false positives) is 0.99995, which equals
0.9995 (assuming independency of tests). However, while there are five
negative challenges per specimen, there are 100 negative challenges for
the laboratory (20 specimens with five challenges per specimen), so the
probability of a laboratory declaring all challenges correctly negative is
0.9999100, which equals 0.9900. That is, the probability of one or more
false positives is 0.0100 (1.0 - 0.9900).
Now, assume that another (higher volume) laboratory receives 100
blank proficiency test specimens that are to be tested for five drugs
each, and that each drug test conducted by the laboratory has an
individual specificity of 0.9999 (that is, the laboratory has a specificity
rate for each drug identical to that of the first laboratory). Again, the
probability that an individual specimen is correctly declared negative
(that is, the probability of no false positives) is 0.99995, which equals
0.9995. However, while there are five negative challenges per specimen,
there are 500 negative challenges for the laboratory (100 specimens with
five challenges per specimen), so the probability of the laboratory
declaring all challenges correctly negative is 0.9999500, which equals
0.9512. That is, the probability of one or more false positives is 0.0488
(1.0 - 0.9512).
14 See 59 Fed. Reg. at 29927, Subpart C, 3.19.
15 See id. at 29924, Subpart B, 2.5(d).
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Thus, the probability that the higher-volume laboratory will report
one or more false positives (0.0488) is nearly five times as high as the
probability for the lower-volume laboratory (0.0100). Therefore, the
higher-volume laboratory will have a much greater probability (than the
lower-volume laboratory) of being disqualified for reporting a false
positive during the initial certification process, and, subsequent to
certification, it will have a much greater probability of reporting a false
positive during routine proficiency testing.
Moreover, because the goal of drug testing is to correctly classify
individuals according to the presence or absence of drugs in their
specimens, the false positive rate for a laboratory does not provide
information relative to the probability of correctly classifying an
individual's specimen. Both hypothetical laboratories have equal
probabilities (0.9995) of correctly classifying a blank specimen when
testing for five drugs, meaning that both laboratories have equal
probabilities (0.0005) of one or more false positives for a given
specimen. However, the probabilities of one or more false positives for
the lower-volume laboratory (0.0100) and for the higher-volume
laboratory (0.0488) are significantly greater than the probability for a
given specimen (0.0005).
This problem becomes even more significant for lower specificity
rates. For example, if the specificity in the above example were 0.9990
rather than 0.9999, the lower-volume laboratory would have a
probability of 0.0952 of reporting one or more false positives, versus
0.3936 for the higher-volume laboratory.
False Negatives and the DHHS Guidelines
The DHHS guidelines also require that a laboratory seeking initial
certification "correctly identify and confirm 90 percent of the total
drug challenges" over the aggregate three cycles of proficiency testing
required for initial certification. 16 Should a certified laboratory
involved in ongoing proficiency testing fail to satisfy a similar 90%
requirement over the span of two consecutive cycles during the required
four cycles of proficiency testing in a given year, suspension or
revocation of certification may result. 17
16 Id. at 29927, Subpart C, 3.19(a)(2).
17 See id. at 29928, Subpart C, 3.19(b)(2).
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The specific wording of these guidelines, requiring the
identification and confirmation of 90% of the total drug challenges,
indicates that negative challenges are not included. The DHHS
guidelines indicate that a screening test should be conducted "to
eliminate 'negative' urine specimens from further consideration and to
identify the presumptively positive specimens that require confirmation
or further testing."18 Since negative test results are not confirmed, the
only challenges subject to confirmation are those that yield positive
results on the screening test: that is, either true positives or false
positives. Because false positives are considered separately under the
DHHS guidelines (as discussed in the previous section), only true
positives (that is, positive results yielded by positive challenges) could
actually be confirmed. Therefore, the DHHS guidelines are equivalent
to a requirement that the laboratory must identify and confirm 90% of
the positive drug challenges; that is, the DHHS term "total drug
challenges" does not include negative challenges. This requirement is
important because mixing positive and negative challenges among
"total challenges" leads to more significant problems. 19
Unfortunately, the more narrow (and more appropriate) DHHS
focus on positive challenges also creates problems because the 90%
requirement is implicitly based on a ratio of sums. We will consider
the implications of ratios of sums relative to single-laboratory and
multiple-laboratory test results.
Implications Relative to a Single Laboratory
Assume we are testing for the presence of two drugs (recall that, at a
minimum, random tests must test for marijuana and cocaine). Further,
suppose that the true sensitivity of the laboratory in detecting the first
drug is 0.95, and the true sensitivity in detecting the second drug is
0.85 (where sensitivity is the probability of a positive test result, given
that the drug is in the specimen). For the first drug, assume there are
twenty positive challenges, and, based on a sensitivity rate of 0.95,
nineteen are identified as positives; that is, there are nineteen (20 x
0.95) true positives. Similarly, for the second drug, assume there are 40
positive challenges and 34 (40 x 0.85) are identified as true positives. If
18 Id. at 29917, Subpart A, 1.2.
19 See generally Barnum & Gleason, supra note 8.
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we use the ratio of sums method to calculate the ability of the
laboratory to detect positive challenges, we have (19+34)/(20+40) =
0.88; that is, 88% of the positive challenges are identified. Recall that
the DHHS guidelines require that at least 90% of the challenges be
identified, which in this example requires the identification of at least
54 (60 x 0.9) challenges, rather than the 53 that are identified.
Instead, assume we have 40 positive challenges for the first drug and
obtain 38 (40 x 0.95) true positives, and 20 positive challenges for the
second drug and obtain 17 (20 x 0.85) true positives. Note that the true
sensitivity of the laboratory in detecting each drug is the same as in the
previous example, and that there is the same total number of positive
challenges (60) as in the previous example. If we use the ratio of sums
method to calculate the ability of the laboratory to detect positive
challenges, we have (38+17)/(40+20) = 0.92; that is, 92% of the positive
challenges are identified. In this case, the DHHS 90% guideline is
satisfied.
Thus, the drug identification rate changes from 88% to 92% solely
because of the change in the relative number of challenges for each
drug. Therefore, the ability of a laboratory to satisfy the 90% DHHS
requirement is dependent upon the relative mix of challenges for each
drug.
Implications Relative to Multiple Laboratories
Consider two laboratories, A and B, each of which is testing for the
presence of two drugs. Suppose that the true sensitivity of Laboratory A
in detecting the first drug is 0.96, and the true sensitivity in detecting
the second drug is 0.87. For the first drug, suppose there are 100
positive challenges which yield 96 (100 x 0.96) true positives; for the
second drug, suppose there are 200 positive challenges which yield 174
(200 x 0.87) true positives. If we use the ratio of sums method to
calculate the ability of the laboratory to detect positive challenges, we
have (96+174)/(100+200) = 0.90.
Now suppose the true sensitivity of Laboratory B in detecting the
first drug is 0.95, and the true sensitivity for the second drug is 0.85.
For the first drug, suppose there are 200 positive challenges which yield
190 (200 x 0.95) true positives; for the second drug, suppose there are
100 positive challenges which yield 85 (100 x 0.85) true positives. Note
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that the total number of positive challenges (300) is identical to that for
Laboratory A. If we use the ratio of sums method to calculate the
ability of Laboratory B to detect positive challenges, we have
(190+85)/(200+100) = 0.92. Thus, the performance of Laboratory B
appears to be better than Laboratory A, even though the ability of
Laboratory A exceeds the ability of Laboratory B to detect the presence
of each drug (0.96 vs. 0.95, and 0.87 vs. 0.85). This result occurs simply
because of the relative mix of the 300 positive challenges for the two
different drugs.
A single change in this example leads to a more troublesome* result.
Suppose the true sensitivity of Laboratory A in testing for the second
drug deteriorates from 0.87 to 0.86. Again, the ability of Laboratory A
to detect the presence of each drug exceeds the ability of Laboratory B.
However, while Laboratory B satisfies the DHHS 90% requirement,
Laboratory A does not satisfy the requirement (it will have identified
only 89% of the positive drug challenges).
Conclusions and Recommendations
Drug-testing programs involve a variety of potential risks: the
personal and economic costs associated with denying or terminating
employment on the basis of faulty test results, legal pitfalls ranging
from the need to satisfy federally-mandated scientific standards
regarding random testing, and issues related to tort liability. To reduce
the risk of inaccurate testing processes, the U.S. government has taken
significant steps to ensure that drug-testing laboratories maintain
extremely high levels of accuracy and also has set rigorous standards to
ensure exemplary laboratory performance. The analysis herein focuses
on only one question: Whether indicators used to measure accuracy are
flawed in ways that result in some drug-testing laboratories being held
to higher standards than others.
The primary conclusion of the Performance Indicator Analysis is
that the proficiency criteria mandated in the DHHS guidelines can
result in differing treatment of laboratories in proficiency tests for both
false positives and false negatives. Laboratories with identical levels of
performance in avoiding false positives (that is, laboratories with
identical specificity levels) can yield different false-positive results
11 Risk. Health, Safety & Environment 297 [Fall 2000]
under the DHHS proficiency-testing process. Similarly, a laboratory
with a superior level of performance in avoiding false negatives (that is,
a laboratory that has a superior sensitivity level in comparison to another
laboratory) can yield poorer false-negative performance under the
DHHS proficiency-testing process. These aberrations are a consequence
of the laboratory focus of the DHHS guidelines. The laboratory-
focused guidelines fail to appropriately measure the true issue of
concern in proficiency testing: the ability of the laboratory to correctly
identify an individual specimen.
These results have several implications. A higher-volume laboratory
may have a greater probability of being disqualified for reporting a false
positive than a lower-volume laboratory during the initial DHHS
certification process. Moreover, subsequent to certification, a higher-
volume laboratory may have a greater probability of reporting a false
positive during routine proficiency testing. Thus, such a laboratory may
have to undertake corrective actions that would not be required of a
lower-volume laboratory with an identical level of proficiency in
avoiding false positives.
On the other hand, with respect to properly identifying true
positives in tests for multiple drugs, the ability of a laboratory to satisfy
the 90% DHHS requirement is dependent upon the relative mix of
challenges for each drug because of the implication of ratios of sums.
An extension of this complication, in tests of more than one laboratory,
is that a superior-performing laboratory can yield a poorer proficiency
result than an inferior-performing laboratory. In such cases, these
misleading outcomes may result in demands for corrective actions that
are not warranted.
The problems with the laboratory-focused DHHS guidelines are
further exacerbated by the regulations developed by various federal
agencies in their attempt to implement the guidelines. As a result,
implementation processes yield even more complications relative to the
true purpose of proficiency testing: to ensure that individual specimens
are correctly identified.
Based on our findings, we recommend that all drug-testing
accuracy indicators used in proficiency-testing processes required by the
DHHS, or by other federal agencies, be subjected to PIA. Measures
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that incorporate potential biases should be replaced with measures that
are free of such errors. Indicators that do not use the individual
specimen as the unit of analysis are especially likely to reflect biases, and
they should be the first to be examined. But even indicators based on
individual specimens can contain criterion errors of the types we have
identified; therefore, they should not be exempt from scrutiny.
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